Martek Announces Fourth Quarter and FY 2007 Financi...(s in the securities class action litigat...)

States District Court for the District of Maryland alleging, among

other things, violations of Section 10(b) and 20(a) of the Securities

Exchange Act of 1934. The settlement will result in the dismissal of

the claims against Martek and all other defendants, subject to final

court approval. The proposed settlement of the class action will

include a cash payment to the settlement fund of $6 million, all of

which will be paid by the Company's insurer. The parties anticipate

filing in the near future a motion in the federal court asking for

approval of the proposed settlement, which is required before the

settlement becomes effective and final. No assurances can be given that

the settlement ultimately will be approved by the court.

-- Developments in Patent Infringement Litigation -- There have been

several recent developments in Martek's patent infringement suits in

the U.S. and Germany, a summary of which follow:

-- Martek Wins German DHA Patent Infringement Actions -- In October

2007, Martek received a favorable judgment in its patent

infringement suit against (i) Lonza Ltd., (ii) Celanese Ventures

GmbH and (iii) Nutrinova Nutrition Specialties & Food Ingredients

GmbH. In a separate suit against Lichtwer Pharma GmbH, one of

Nutrinova's customers, a similar judgment was announced. The first

suit involves Lonza's German sale and use of a fatty acid product

currently marketed under the brand name Lonza DHA for use in

functional foods and dietary supplements. The second suit involves

Lichtwer's German sale and use of a DHA-containing oil in a

supplement marketed under the brand name AMEU(R) Alge. The decisions

may be appealed by Lonza and Lichtwe
'/>"/>